Denmark

Del

Links

Vælg en periode -
Tags ( Aktiv)

Västra Hamnen: ViroGates - Success in anakinra study

Västra Hamnen Corporate Finance has published a research update on ViroGates following its report for Q1 2021 and the result of the phase III anakinra study. The successful study suggests accellerated sales growth and we raise our valuation interval, writes Västra Hamnen.· Q1 revenue and net loss slightly weaker than our estimates · Anakinra success should accelerate demand and we raise our forecasts · New valuation interval of DKK 115.00 – 180.00 (DKK 104.20 – 162.00) per share Last week’s release of ViroGates’ Q1 report contained no big surprises. Revenues were slightly lower

Invitation to ViroGates’ presentation of Q1 2021 report

Press release 28.04.2021ViroGates A/S will publish its Interim Report for Q1 2021 on Thursday 29 April, 2021. On Monday 3 May, 2021 at 10.00 CEST, the company will join a web conference hosted by Västra Hamnen Corporate Finance to present a summary of the report. The company will be represented by CEO Jakob Knudsen and CFO Mark Christian Hvidberg da Silva. After their presentation, there will be a Q/A session. The conference will be held in English. You can join the conference by computer or mobile devices.The number of participants is limited and we recommend signing up early in order

Västra Hamnen: ViroGates - Steady progress

Västra Hamnen Corporate Finance has published a research update on ViroGates following its Annual Report for 2020. The report shows progress on many fronts. Now including the market for forthcoming POC product in our valuation model, we raise our fair value interval for the share, writes Västra Hamnen.· Annual report shows progress on many fronts · suPARnostic POC+ to launch later this year, adding significant market potential · We raise our assessment of fair value to 104.20 – 162.00 DKK per share ViroGates’ annual report last week documented advances in several exciting

Västra Hamnen: ViroGates - Detects COVID-19 relevance

Västra Hamnen Corporate Finance has published a research update on ViroGates following its Quarterly Report for Q1 2020. The numbers were largely in line with expectations. The bigger news is an early indication that suPAR can be helpful in triaging COVID-19 patients, writes Västra Hamnen.· suPAR determines severity of COVID-19 in preliminary study · Steady increase in hospitals evaluating suPARnostic® for clinical use · We keep our valuation interval unchanged ViroGates published its quarterly report for Q1 2020 last week. The figures showed somewhat lower revenues, but even lower

Västra Hamnen: ViroGates - Better days to come

Västra Hamnen Corporate Finance has published a research update on ViroGates following its Annual Report for 2019. We see increased uncertainty but lean towards improved long-term outlook, writes Västra Hamnen.· COVID-19 raises awareness of the benefits of suPAR testing · Financial target reduced but pilot customers increased · We reiterate our fair value interval of DKK 68.50 – 100.50 per share We have reviewed our analysis of ViroGates following the release of its Annual Report for 2019 last week. We have seen both good and bad news since our Initial Research report in January.

ViroGates: A suPARhighway to health (Västra Hamnen)

Västra Hamnen Corporate Finance initiates research coverage on the Danish medical technology company ViroGates A/S. The initial valuation range is set at DKK 68.00 - 100.50 per share given the present level of risk.· A simple blood test to immensely improve clinical decision making · Global market opportunities and virtually no competition · We see a fair value of DKK 68.00 – 100.50 per share in Acute Care alone ViroGates has developed a prognostic biomarker, suPARnostic®, that can assist physicians in deciding which patients need immediate attention and which patients can safely

Der er ikke nogen emner der matcher det aktuelle filter
Der er ikke flere emner der matcher det aktuelle filter
Tilbage til toppen